dimethyleicosylammoniohexanoate | 72861-47-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: dimethyleicosylammoniohexanoate
• 英文别名: 6-(Eicosyldimethylammonio) hexanoate；6-[icosyl(dimethyl)azaniumyl]hexanoate
• CAS: 72861-47-3
• 化学式: C₂₈H₅₇NO₂
• 分子量: 439.766
• InChiKey: CXSZOYWCYJWWOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.4
• 重原子数：
  31
• 可旋转键数：
  24
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  40.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  Decyl-(5-ethoxycarbonyl-pentyl)-dimethyl-ammonium; bromide 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 dimethyleicosylammoniohexanoate
  参考文献：
  名称：

  6-(Alkyldimethylammonio)-hexanoates

  摘要：

  DOI：

  10.1055/s-1984-30862

文献信息

• Solvent systems for pharmaceutical agents
  申请人：——

  公开号：US20020102280A1

  公开（公告）日：2002-08-01

  The invention provides compositions, solvent systems, and methods for solubilizing compounds which are otherwise difficult to solubilize. The invention involves the use of a structured fluid (e.g. a liquid crystalline phase, an L1 phase, an L2 phase, an L3 phase, an emulsion, or a microemulsion), comprising a polar solvent, a lipid or a surfactant, and an essential oil or a dissolution/solubilization agent.

  这项发明提供了用于溶解那些通常难以溶解的化合物的组合物、溶剂系统和方法。该发明涉及使用结构化流体（例如液晶相、L1相、L2相、L3相、乳化液或微乳化液），其中包括极性溶剂、脂质或表面活性剂以及精油或溶解/溶解剂。
• Particles with improved solubilization capacity
  申请人：——

  公开号：US20030022242A1

  公开（公告）日：2003-01-30

  A particle is disclosed that comprises a first volume of hydrophobe-rich material with tunable dissolution and solubilization characteristics and a distinct second volume of nanostructured nonlamellar liquid crystalline material, said second volume containing said first domain and being capable of being in equilibrium with said first volume. Preferably, the nanostructured nonlamellar liquid crystalline material is capable of being in equilibrium with a polar solvent or a water-immiscible solvent or both.

  揭示了一种颗粒，包括具有可调溶解和溶解特性的第一体积的疏水基质材料和独特的第二体积的纳米结构非层状液晶材料，所述第二体积包含所述第一领域，并能够与所述第一体积处于平衡状态。优选，所述纳米结构非层状液晶材料能够与极性溶剂或水不相溶溶剂或两者同时处于平衡状态。
• COATED PARTICLES, METHODS OF MAKING AND USING
  申请人：——

  公开号：US20040201117A1

  公开（公告）日：2004-10-14

  A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least on nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

  涂覆有非层状材料（如非层状晶体材料、非层状非晶态材料或非层状半晶态材料）的粒子，包括具有至少一个纳米结构液相或至少一个纳米结构液晶相或两者的组合的内部基质核心，用于传递活性剂，如药物、营养素、杀虫剂等。涂覆的粒子可以通过各种不同的技术制造，其中外部涂层是非层状材料，如非层状晶体材料、非层状非晶态材料或非层状半晶态材料。
• Coated particles, methods of making and using
  申请人：——

  公开号：US20030108743A1

  公开（公告）日：2003-06-12

  A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least on nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

  涂覆有非层状材料的颗粒，例如非层状晶体材料、非层状非晶材料或非层状半晶材料，包括至少一个纳米结构液相的内部基质核心，或至少一个纳米结构液晶相或两者的组合，用于传递活性物质，如药物、营养素、杀虫剂等。涂覆的颗粒可以通过各种不同的技术制造，其中外部涂层是非层状材料，例如非层状晶体材料、非层状非晶材料或非层状半晶材料。
• Treatment using dantrolene
  申请人：Lyotropic Therapeutics, Inc.

  公开号：US10314822B2

  公开（公告）日：2019-06-11

  Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.

  与目前已获批准并在市场上销售的用于治疗恶性高热（MH）危及麻醉危机的丹曲林相比，我们提供的小剂量、安全注射型丹曲林制剂具有显著优势。一旦丹曲林可以立即用于触发恶性高热的患者，麻醉医师就能在这种复杂多变的危机中专注于患者生理状态的管理，而不是费力费时的解救剂重组过程。丹曲林的注射剂量小、安全性高，与目前使用的预防和治疗泵头及其他因先天性或外伤引起的血流改变导致的神经、认知和运动功能障碍的方法相比具有显著优势，包括在涉及 CPB 或相关程序的手术过程中发生的泵头及其他因先天性或疾病引起的非正常体温事件中发生的泵头及其他神经、认知和运动功能障碍。